로딩 중…
지수 로딩 중…
DT&CRO CO., Ltd.
383930· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩2,225-3.89%
2026-06-19
Price Chart
DT&CRO CO., Ltd.-41.91%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 28.44B KRW |
| Revenue | 47.77B KRW |
| Net Income | 2.74B KRW |
| Total Assets | 93.97B KRW |
| Net Assets | 11.31B KRW |
| Employees | 333 |
| Value | |
| P/E | 10.37x |
| P/B | 2.51x |
| P/S | 0.60x |
| EV/EBITDA | 143.25x |
| FCF Yield | -43.57% |
| Profitability | |
| ROE | 24.25% |
| ROA | 2.92% |
| Op. Margin | 1.10% |
| Revenue Growth | 0.20% |
| Earnings Growth | -71.70% |
| Financial Health | |
| Debt Ratio | 830.68% |
| Total Debt | 49.48B KRW |
| FCF | -12.39B KRW |
| Cash | 2.88B KRW |
| Current Ratio | 0.66x |
| Net Debt/EBITDA | 88.96x |
| Performance | |
| 1Y Return | -41.91% |
| 1M Return | -3.89% |
| From 52W High | -49.20% |
| 1Y MDD | -74.02% |
| Trading | |
| Volume | 125,478 shares |
| Foreign Own. | 3.78% |
| Per Share | |
| EPS | -961 KRW |
| BPS | 885 KRW |
Company Info
Established in 2017 as a CRO providing non-clinical and clinical trial services across various fields, DT&CRO listed on KOSDAQ in 2022. The company conducts non-clinical tests like efficacy, pharmacokinetic, and GLP toxicology studies, as well as bioequivalence and clinical trials, and signed an FDA IND consulting MOU with a US research company in 2024. DT&CRO offers one-stop services from non-clinical to clinical and regulatory approval, emerging as a CRO industry leader through initiatives like AI-powered smart clinical trial platform development. DT&CRO is headquartered in Yongin-si, Gyeonggi-do.